시장보고서
상품코드
1301160

헬스케어 CDMO(Contract Development And Manufacturing Organization) 시장 규모, 점유율, 동향 분석 보고서 : 서비스별(수탁개발, 수탁제조), 지역별, 부문별 예측(2023-2030년)

Healthcare Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Services (Contract Development, Contract Manufacturing), By Region, And Segment Forecasts, 2023 - 2030

발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 175 Pages | 배송안내 : 2-10일 (영업일 기준)


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

헬스케어 CDMO(Contract Development And Manufacturing Organization) 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 헬스케어 CDMO 시장 규모는 2030년까지 4,710억 달러에 달할 것으로 예상됩니다.

이 시장은 2023-2030년 연평균 9.5%의 성장률을 기록할 것으로 예상됩니다. 이 시장은 R&D 비용 증가와 아웃소싱 동향의 증가로 인해 유리한 성장세를 보일 것으로 예상됩니다.

헬스케어 CDMO는 다양한 제약 산업에 아웃소싱 서비스를 계약 기반으로 제공합니다. 제약 기업의 아웃소싱 증가, 제약 산업의 확장, CDMO의 운영 및 자본 비용 절감 지원은 예측 기간 중 시장 성장을 가속할 것으로 예상되는 주요 요인 중 일부입니다.

또한 제약 및 의료기기 기업에 대한 엄격한 일정 준수에 대한 압박이 증가함에 따라 CDMO에 대한 개발 및 제조 활동의 아웃소싱 수요가 증가하고 있습니다. 또한 신흥 국가에서의 의료기기 수요 증가로 인해 다양한 기업이 의료기기 수탁개발 및 제조를 위한 R&D 활동에 집중하고 있습니다. 지난 10년간 일부 제약사들은 자사의 신규 혁신 제품의 사전 포뮬레이션과 개발 및 제조를 지원하기 위해 CMO, CRO, CDMO로 눈을 돌리고 있습니다. 아웃소싱은 고성장 시장이며, 대부분의 지출은 초기 개발에 집중되어 있습니다.

신약 파이프라인의 약 75%는 중견 및 중소 바이오 제약사가 보유하고 있습니다. 이 기업은 수익성이 높아 비용 절감을 원하는 의료 서비스 프로바이더들에게 좋은 타겟이 되고 있습니다. 따라서 이들 기업은 자체 인프라 구축에 투자하는 대신 전문 지식과 필요한 장비를 갖춘 제3의 기관에 서비스를 위탁하는 것이 이익이 됩니다. 일부 제약사들은 분자 개발을 최적화하기 위해 아웃소싱 서비스를 찾고 있습니다. 예를 들어 미국 바이오 기업 Remedium Bio는 2023년 3월 벨기에에 위치한 CDMO Exothera와 Remedium의 주요 유전자 치료제 후보물질인 골관절염 치료제 AAV2-FGF18의 생산 규모를 확대하기 위한 제휴 계약을 체결했습니다.

그러나 물류 비용의 증가, 의료 기관이 직면한 시리얼화 문제, 지적재산권(IP) 침해의 위협은 예측 기간 중 헬스케어 CDMO 시장 성장을 억제할 것으로 예상됩니다.

헬스케어 CDMO 시장 보고서 하이라이트

  • 제약 및 의료기기 기업별 제조 서비스 아웃소싱 증가로 2022년 시장 매출 점유율은 제조 위탁 부문이 73.5%로 시장을 장악했습니다.
  • 저분자 화합물 수탁개발 하위 부문별로는 신약 파이프라인 증가로 인해 전임상/부문이 예측 기간 중 10.4%의 가장 높은 CAGR을 기록할 것으로 예상됩니다.
  • 북미는 2022년 40.9%로 가장 큰 매출 점유율을 차지하며 헬스케어 CDMO 시장을 장악했습니다. 이 지역의 높은 점유율은 이 지역, 특히 미국에서 활발하게 활동하는 CRO와 CMO가 많기 때문입니다.
  • 아시아태평양은 예측 기간 중 10.4%의 가장 빠른 CAGR로 성장할 것으로 예상됩니다. 이 지역은 아시아 지역 CRO 및 CMO가 제공하는 저비용 개발 및 제조 위탁 서비스로 인해 유리한 CAGR을 기록할 것으로 예상됩니다.

목차

제1장 조사 방법과 범위

  • 시장 세분화와 범위
    • 부문의 정의
    • 서비스
  • 지역의 범위
  • 추정·예측 타임라인
  • 목적
  • 조사 방법
  • 정보 조달
    • 구입한 데이터베이스
    • GVR의 내부 데이터베이스
    • 2차 정보
    • 1차 조사
  • 정보 또는 데이터 분석
    • 데이터 분석 모델
  • 시장 형성과 검증
  • 모델 상세
    • 상품 플로우 분석
    • 모시장 분석
  • 2차 정보 리스트
  • 약어 리스트

제2장 주요 요약

  • 시장 전망
  • 부문 전망
  • 경쟁 인사이트

제3장 헬스케어 CDMO 시장 변수, 동향, 범위

  • 시장 계통 전망
    • 모시장 전망
    • 관련/보조적인 시장 전망
  • 서비스별제품 파이프라인 분석
  • 시장 역학
    • 시장 촉진요인 분석
    • 시장 억제요인 분석
  • 헬스케어 CDMO 시장 분석 툴
    • 업계 분석 : Porter의 산업 분석
    • PESTEL 분석
    • COVID-19의 영향 분석
    • 주요 거래와 전략적 제휴 분석

제4장 헬스케어 CDMO 시장 : 서비스 추정·동향 분석

  • 헬스케어 CDMO 시장, 서비스별 : 부문 대시보드
  • 헬스케어 CDMO 시장, 서비스별 : 변동 분석
    • 수탁개발
    • 수탁제조

제5장 헬스케어 CDMO 시장 : 지역 추정·동향 분석

  • 지역 시장 점유율 분석, 2022년 및 2030년
  • 지역 시장 대시보드
  • 세계의 지역 시장 스냅숏
  • 북미
    • 시장 추산·예측, 2018-2030년(매출, 100만 달러)
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 덴마크
    • 스웨덴
    • 노르웨이
    • 네덜란드
    • 벨기에
  • 아시아태평양
    • 일본
    • 인도
    • 중국
    • 한국
    • 호주
    • 태국
    • 말레이시아
    • 뉴질랜드
    • 싱가포르
    • 필리핀
  • 라틴아메리카
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 칠레
  • MEA
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트
    • 쿠웨이트
    • 이스라엘

제6장 경쟁 구도

  • 시장 참여 기업의 분류
    • 이노베이터
    • 시장 리더
    • 신규 기업
    • 기업의 시장 점유율 분석, 2022년
  • 기업 개요
    • Catalent Inc.
    • Lonza
    • Recipharm AB
    • Siegfried Holding AG
    • Thermo Fisher Scientific, Inc
    • Labcorp Drug Development
    • Jabil Inc
    • Syngene International Limited
    • IQVIA Inc.
    • Almac Group
    • Ajinomoto Bio-Pharma
    • Adare Pharma Solutions
    • Alcami Corporation
    • Vetter Pharma International

제7장 KoL 해설/권장사항

KSA 23.07.24

Healthcare Contract Development And Manufacturing Organization Market Growth & Trends

The global healthcare contract development and manufacturing organization market size is expected to reach USD 471.0 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 9.5% from 2023 to 2030. The market is expected to show lucrative growth due to increasing R&D expenditure and rising outsourcing trends.

Healthcare Contract Development and Manufacturing Organization (CDMO) provide outsourcing services to various pharmaceutical industries on a contract basis. An increase in outsourcing by pharmaceutical companies, expansions in the pharmaceutical industry, and the support of CDMOs in reducing operational and capital expenses are some of the major factors anticipated to propel the market growth in the forecast period.

In addition, growing pressure on pharmaceutical and medical device companies to follow stringent timelines has increased the demand for outsourcing development and manufacturing activities to CDMOs. Further, due to the increasing demand for medical devices in emerging countries, various companies are shifting their focus on research and development activities for medical device contract development and manufacturing. Over the past 10 years, several pharmaceutical companies have turned to CMOs, CROs, and CDMOs to assist in preformulation and development & manufacturing of their novel innovations. Outsourcing is a high growth market and most spending is focused on early development.

Around 75% of new drug pipelines come from small and midsized biopharmaceutical companies. These companies have high profit margins, which make them easy targets for healthcare providers who are trying to reduce cost. Thus, instead of investing in establishing their own infrastructure, it is profitable for these companies to outsource services to third-party organizations who have expertise and the required equipment. Several pharmaceutical companies are seeking outsourced services for optimizing the development of their molecule. For instance, in March 2023, Remedium Bio, a U.S.-based biotechnology company, entered in a collaboration agreement with Exothera, a Belgium-based CDMO, to scale up the production of Remedium's lead gene therapy drug candidate, AAV2-FGF18 in the treatment of osteoarthritis.

However, increasing logistic costs, serialization issues faced by healthcare organizations, and the threat of infringement of Intellectual Property (IP) rights are anticipated to restrain the market growth for healthcare contract development & manufacturing organization over the forecast period.

Healthcare Contract Development And Manufacturing Organization Market Report Highlights

  • The contract manufacturing segment dominated the market with a revenue share of 73.5% in 2022 due to increase in the outsourcing of manufacturing services by pharmaceutical and medical device companies
  • By small molecule contract development sub-segment, the preclinical/segment is expected to register the highest CAGR of 10.4% in the forecast period due to the rising pipeline of novel therapeutics
  • North America dominated the healthcare contract development and manufacturing organization market with the largest revenue share of 40.9% in 2022. High shares of the region are majorly due to the presence of a large number of actively functioning CROs and CMOs in the region, especially across the U.S.
  • The Asia Pacific is projected to witness the fastest CAGR of 10.4% during the forecast period. The region is anticipated to witness a lucrative CAGR owing to the low-cost contract development and manufacturing services offered by Asian CROs and CMOs

Table of Contents

Chapter 1. Research Methodology And Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
    • 1.1.2. Services
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. Parent Market Analysis
  • 1.10. List Of Secondary Sources
  • 1.11. List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Healthcare CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Product Pipeline Analysis, by Service
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
      • 3.3.1.1. Increasing Outsourcing Services By Pharmaceutical Companies
      • 3.3.1.2. Rising Investment In R&D
      • 3.3.1.3. Growing Pharmaceutical Industry
      • 3.3.1.4. Increasing Demand For One-Stop-Shop CDMOs
    • 3.3.2. Market Restraint Analysis
      • 3.3.2.1. Compliance Issues While Outsourcing
      • 3.3.2.2. Changing Scenarios In Developing Countries
      • 3.3.2.3. Regulatory And Legal Compliance
  • 3.4. Healthcare CDMO Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier Power
      • 3.4.1.2. Buyer Power
      • 3.4.1.3. Substitution Threat
      • 3.4.1.4. Threat Of New Entrant
      • 3.4.1.5. Competitive Rivalry
    • 3.4.2. PESTEL Analysis
    • 3.4.3. COVID-19 Impact Analysis
    • 3.4.4. Major Deals & Strategic Alliances Analysis
      • 3.4.4.1. Mergers & Acquisitions
      • 3.4.4.2. Geographic Expansions
      • 3.4.4.3. Partnerships
      • 3.4.4.4. Launch
      • 3.4.4.5. Collaborations

Chapter 4. Healthcare CDMO Market: Services Estimates & Trend Analysis

  • 4.1. Healthcare CDMO Market, By Services: Segment Dashboard
  • 4.2. Healthcare CDMO Market, By Services: Movement Analysis
  • 4.3. Healthcare CDMO Market Estimates & Forecasts, By Services, 2018 - 2030
    • 4.3.1. Contract Development
      • 4.3.1.1. Contract Development Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2. Small Molecule
      • 4.3.1.2.1. Small Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.2. Preclinical
      • 4.3.1.2.2.1. Preclinical Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.2.2. Bioanalysis and DMPK studies
      • 4.3.1.2.2.2.1. Bioanalysis and DMPK studies Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.2.3. Toxicology Testing
      • 4.3.1.2.2.3.1. Toxicology Testing Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.2.4. Other Preclinical Services
      • 4.3.1.2.2.4.1. Other Preclinical Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.3. Clinical
      • 4.3.1.2.3.1. Clinical Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.3.2. Phase I
      • 4.3.1.2.3.2.1. Phase I Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.3.3. Phase II
      • 4.3.1.2.3.3.1. Phase II Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.3.4. Phase III
      • 4.3.1.2.3.4.1. Phase III Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.3.5. Phase IV
      • 4.3.1.2.3.5.1. Phase IV Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.4. Laboratory Services
      • 4.3.1.2.4.1. Laboratory Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.4.2. Bioanalytical Services
      • 4.3.1.2.4.2.1. Bioanalytical Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.4.3. Analytical Services
      • 4.3.1.2.4.3.1. Analytical Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3. Large Molecule
      • 4.3.1.3.1. Large Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.2. Cell line development
      • 4.3.1.3.2.1. Cell line development Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3. Process Development
      • 4.3.1.3.3.1. Process Development Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.2. Upstream
      • 4.3.1.3.3.2.1. Upstream Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.2.2. Microbial
      • 4.3.1.3.3.2.2.1. Microbial Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.2.3. Mammalian
      • 4.3.1.3.3.2.3.1. Mammalian Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.2.4. Others
      • 4.3.1.3.3.2.4.1. Others Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.3. Downstream
      • 4.3.1.3.3.3.1. Downstream Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.3.2. MABs
      • 4.3.1.3.3.3.2.1. MABs Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.3.3. Recombinant Proteins
      • 4.3.1.3.3.3.3.1. Recombinant Proteins Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.3.4. Others
      • 4.3.1.3.3.3.4.1. Others Healthcare CDMO Market, 2018 to 2030 (USD Million)
    • 4.3.2. Contract Manufacturing
      • 4.3.2.1. Contract Manufacturing Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.2. Small Molecule
      • 4.3.2.2.1. Small Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.3. Large Molecule
      • 4.3.2.3.1. Large Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.3.2. MABs
      • 4.3.2.3.2.1. MABs Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.3.3. Recombinant Proteins
      • 4.3.2.3.3.1. Recombinant Proteins Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.3.4. Others
      • 4.3.2.3.4.1. Others Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.4. High Potency API
      • 4.3.2.4.1. High Potency API Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.5. Finished Dose Formulations
      • 4.3.2.5.1. Finished Dose Formulations Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.5.2. Solid Dose Formulation
      • 4.3.2.5.2.1. Solid Dose Formulation Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.5.3. Liquid Dose Formulation
      • 4.3.2.5.3.1. Liquid Dose Formulation Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.5.4. Injectable Dose Formulation
      • 4.3.2.5.4.1. Injectable Dose Formulation Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.6. Medical Device
      • 4.3.2.6.1. Medical Device Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.6.2. Class I
      • 4.3.2.6.2.1. Class I Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.6.3. Class II
      • 4.3.2.6.3.1. Class II Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.6.4. Class III
      • 4.3.2.6.4.1. Class III Healthcare CDMO Market, 2018 to 2030 (USD Million)

Chapter 5. Healthcare CDMO Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Share Analysis, 2022 & 2030
  • 5.2. Regional Market Dashboard
  • 5.3. Global Regional Market Snapshot
  • 5.4. North America
    • 5.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. U.S.
      • 5.4.2.1. Key Country Dynamics
      • 5.4.2.2. Competitive Scenario
      • 5.4.2.3. Regulatory Framework
      • 5.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 5.4.3. Canada
      • 5.4.3.1. Key Country Dynamics
      • 5.4.3.2. Competitive Scenario
      • 5.4.3.3. Regulatory Framework
      • 5.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
  • 5.5. Europe
    • 5.5.1. UK
      • 5.5.1.1. Key Country Dynamics
      • 5.5.1.2. Competitive Scenario
      • 5.5.1.3. Regulatory Framework
      • 5.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    • 5.5.2. Germany
      • 5.5.2.1. Key Country Dynamics
      • 5.5.2.2. Competitive Scenario
      • 5.5.2.3. Regulatory Framework
      • 5.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    • 5.5.3. France
      • 5.5.3.1. Key Country Dynamics
      • 5.5.3.2. Competitive Scenario
      • 5.5.3.3. Regulatory Framework
      • 5.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    • 5.5.4. Italy
      • 5.5.4.1. Key Country Dynamics
      • 5.5.4.2. Competitive Scenario
      • 5.5.4.3. Regulatory Framework
      • 5.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    • 5.5.5. Spain
      • 5.5.5.1. Key Country Dynamics
      • 5.5.5.2. Competitive Scenario
      • 5.5.5.3. Regulatory Framework
      • 5.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    • 5.5.6. Denmark
      • 5.5.6.1. Key Country Dynamics
      • 5.5.6.2. Competitive Scenario
      • 5.5.6.3. Regulatory Framework
      • 5.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    • 5.5.7. Sweden
      • 5.5.7.1. Key Country Dynamics
      • 5.5.7.2. Competitive Scenario
      • 5.5.7.3. Regulatory Framework
      • 5.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    • 5.5.8. Norway
      • 5.5.8.1. Key Country Dynamics
      • 5.5.8.2. Competitive Scenario
      • 5.5.8.3. Regulatory Framework
      • 5.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
    • 5.5.9. Netherlands
      • 5.5.9.1. Key Country Dynamics
      • 5.5.9.2. Competitive Scenario
      • 5.5.9.3. Regulatory Framework
      • 5.5.9.4. Netherlands Market Estimates and Forecasts, 2018 - 2030
    • 5.5.10. Belgium
      • 5.5.10.1. Key Country Dynamics
      • 5.5.10.2. Competitive Scenario
      • 5.5.10.3. Regulatory Framework
      • 5.5.10.4. Belgium Market Estimates and Forecasts, 2018 - 2030
  • 5.6. Asia Pacific
    • 5.6.1. Japan
      • 5.6.1.1. Key Country Dynamics
      • 5.6.1.2. Competitive Scenario
      • 5.6.1.3. Regulatory Framework
      • 5.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    • 5.6.2. India
      • 5.6.2.1. Key Country Dynamics
      • 5.6.2.2. Competitive Scenario
      • 5.6.2.3. Regulatory Framework
      • 5.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
    • 5.6.3. China
      • 5.6.3.1. Key Country Dynamics
      • 5.6.3.2. Competitive Scenario
      • 5.6.3.3. Regulatory Framework
      • 5.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
    • 5.6.4. South Korea
      • 5.6.4.1. Key Country Dynamics
      • 5.6.4.2. Competitive Scenario
      • 5.6.4.3. Regulatory Framework
      • 5.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    • 5.6.5. Australia
      • 5.6.5.1. Key Country Dynamics
      • 5.6.5.2. Competitive Scenario
      • 5.6.5.3. Regulatory Framework
      • 5.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    • 5.6.6. Thailand
      • 5.6.6.1. Key Country Dynamics
      • 5.6.6.2. Competitive Scenario
      • 5.6.6.3. Regulatory Framework
      • 5.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
    • 5.6.7. Malaysia
      • 5.6.7.1. Key Country Dynamics
      • 5.6.7.2. Competitive Scenario
      • 5.6.7.3. Regulatory Framework
      • 5.6.7.4. Malaysia Market Estimates and Forecasts, 2018 - 2030
    • 5.6.8. New Zealand
      • 5.6.8.1. Key Country Dynamics
      • 5.6.8.2. Competitive Scenario
      • 5.6.8.3. Regulatory Framework
      • 5.6.8.4. New Zealand Market Estimates and Forecasts, 2018 - 2030
    • 5.6.9. Singapore
      • 5.6.9.1. Key Country Dynamics
      • 5.6.9.2. Competitive Scenario
      • 5.6.9.3. Regulatory Framework
      • 5.6.9.4. Singapore Market Estimates and Forecasts, 2018 - 2030
    • 5.6.10. Philippines
      • 5.6.10.1. Key Country Dynamics
      • 5.6.10.2. Competitive Scenario
      • 5.6.10.3. Regulatory Framework
      • 5.6.10.4. Philippines Market Estimates and Forecasts, 2018 - 2030
  • 5.7. Latin America
    • 5.7.1. Brazil
      • 5.7.1.1. Key Country Dynamics
      • 5.7.1.2. Competitive Scenario
      • 5.7.1.3. Regulatory Framework
      • 5.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    • 5.7.2. Mexico
      • 5.7.2.1. Key Country Dynamics
      • 5.7.2.2. Competitive Scenario
      • 5.7.2.3. Regulatory Framework
      • 5.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
    • 5.7.3. Argentina
      • 5.7.3.1. Key Country Dynamics
      • 5.7.3.2. Competitive Scenario
      • 5.7.3.3. Regulatory Framework
      • 5.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
    • 5.7.4. Colombia
      • 5.7.4.1. Key Country Dynamics
      • 5.7.4.2. Competitive Scenario
      • 5.7.4.3. Regulatory Framework
      • 5.7.4.4. Colombia Market Estimates and Forecasts, 2018 - 2030
    • 5.7.5. Chile
      • 5.7.5.1. Key Country Dynamics
      • 5.7.5.2. Competitive Scenario
      • 5.7.5.3. Regulatory Framework
      • 5.7.5.4. Chile Market Estimates and Forecasts, 2018 - 2030
  • 5.8. MEA
    • 5.8.1. South Africa
      • 5.8.1.1. Key Country Dynamics
      • 5.8.1.2. Competitive Scenario
      • 5.8.1.3. Regulatory Framework
      • 5.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    • 5.8.2. Saudi Arabia
      • 5.8.2.1. Key Country Dynamics
      • 5.8.2.2. Competitive Scenario
      • 5.8.2.3. Regulatory Framework
      • 5.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    • 5.8.3. UAE
      • 5.8.3.1. Key Country Dynamics
      • 5.8.3.2. Competitive Scenario
      • 5.8.3.3. Regulatory Framework
      • 5.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    • 5.8.4. Kuwait
      • 5.8.4.1. Key Country Dynamics
      • 5.8.4.2. Competitive Scenario
      • 5.8.4.3. Regulatory Framework
      • 5.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030
    • 5.8.5. Israel
      • 5.8.5.1. Key Country Dynamics
      • 5.8.5.2. Competitive Scenario
      • 5.8.5.3. Regulatory Framework
      • 5.8.5.4. Israel Market Estimates and Forecasts, 2018 - 2030

Chapter 6. Competitive Landscape

  • 6.1. Market Participant Categorization
    • 6.1.1. Innovators
    • 6.1.2. Market Leaders
    • 6.1.3. Emerging Players
    • 6.1.4. Company Market Share Analysis, 2022
  • 6.2. Company Profiles
    • 6.2.1. Catalent Inc.
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Financial Performance
      • 6.2.1.3. Service Benchmarking
      • 6.2.1.4. Strategic Initiatives
    • 6.2.2. Lonza
      • 6.2.2.1. Company Overview
      • 6.2.2.2. Financial Performance
      • 6.2.2.3. Service Benchmarking
      • 6.2.2.4. Strategic Initiatives
    • 6.2.3. Recipharm AB
      • 6.2.3.1. Company Overview
      • 6.2.3.2. Financial Performance
      • 6.2.3.3. Service Benchmarking
      • 6.2.3.4. Strategic Initiatives
    • 6.2.4. Siegfried Holding AG
      • 6.2.4.1. Company Overview
      • 6.2.4.2. Financial Performance
      • 6.2.4.3. Service Benchmarking
      • 6.2.4.4. Strategic Initiatives
    • 6.2.5. Thermo Fisher Scientific, Inc
      • 6.2.5.1. Company Overview
      • 6.2.5.2. Financial Performance
      • 6.2.5.3. Service Benchmarking
      • 6.2.5.4. Strategic Initiatives
    • 6.2.6. Labcorp Drug Development
      • 6.2.6.1. Company Overview
      • 6.2.6.2. Financial Performance
      • 6.2.6.3. Service Benchmarking
      • 6.2.6.4. Strategic Initiatives
    • 6.2.7. Jabil Inc
      • 6.2.7.1. Company Overview
      • 6.2.7.2. Financial Performance
      • 6.2.7.3. Service Benchmarking
      • 6.2.7.4. Strategic Initiatives
    • 6.2.8. Syngene International Limited
      • 6.2.8.1. Company Overview
      • 6.2.8.2. Financial Performance
      • 6.2.8.3. Service Benchmarking
      • 6.2.8.4. Strategic Initiatives
    • 6.2.9. IQVIA Inc.
      • 6.2.9.1. Company Overview
      • 6.2.9.2. Financial Performance
      • 6.2.9.3. Service Benchmarking
      • 6.2.9.4. Strategic Initiatives
    • 6.2.10. Almac Group
      • 6.2.10.1. Company Overview
      • 6.2.10.2. Financial Performance
      • 6.2.10.3. Service Benchmarking
      • 6.2.10.4. Strategic Initiatives
    • 6.2.11. Ajinomoto Bio-Pharma
      • 6.2.11.1. Company Overview
      • 6.2.11.2. Financial Performance
      • 6.2.11.3. Service Benchmarking
      • 6.2.11.4. Strategic Initiatives
    • 6.2.12. Adare Pharma Solutions
      • 6.2.12.1. Company Overview
      • 6.2.12.2. Financial Performance
      • 6.2.12.3. Service Benchmarking
      • 6.2.12.4. Strategic Initiatives
    • 6.2.13. Alcami Corporation
      • 6.2.13.1. Company Overview
      • 6.2.13.2. Financial Performance
      • 6.2.13.3. Service Benchmarking
      • 6.2.13.4. Strategic Initiatives
    • 6.2.14. Vetter Pharma International
      • 6.2.14.1. Company Overview
      • 6.2.14.2. Financial Performance
      • 6.2.14.3. Service Benchmarking
      • 6.2.14.4. Strategic Initiatives

Chapter 7. KoL Commentary/Recommendations

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제